Mylan And India’s Biocon Team Up To Develop Insulin Biosimilars Of Sanofi, Lilly, Novo Nordisk Products
This article was originally published in The Pink Sheet Daily
Less than a year after Pfizer broke out of a deal with Biocon, the company announced it is linking up with Mylan to make biosimilars of insulin products made by Sanofi, Lilly and Novo Nordisk.
You may also be interested in...
Consolidation in the generic industry is good and necessary, Mylan CEO Heather Bresch said during a recent investor presentation. Mylan is well-positioned in the changing market, she said, thanks to business development such as its biosimilars agreements with Biocon and its Japan collaboration with Pfizer.
The generic market is moving toward more complex products and formulations, which will separate companies based on capabilities, CEOs said at the Generic Pharmaceutical Association annual meeting.
Pfizer tells analysts the deal will have an incremental not "instrumental" impact on its established products and emerging markets strategy.